Clinical Trial

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-01-14; most recent amendment 2026-04-23.
Status change: Active, Not Recruiting → Recruiting 2026-03-10
Status change: Recruiting → Active, Not Recruiting 2025-12-03
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06782373
Lead Sponsor Swedish Orphan Biovitrum
Collaborators: PSI CRO
Conditions VEXAS, VEXAS Syndrome
Enrollment 78 participants
Start Date 2025-05-28
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-05-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-24